BioCryst Pharmaceuticals Inc (BCRX) Dividend History

Company News

• AscellaHealth’s Patient-Focused Approach is Best-in-Class Model for Distribution of Rare Disease Therapies

  AscellaHealth highlights its customizable distribution model for specialty and rare disease pharmaceutical therapies, emphasizing a patient-first approach that offers personalized support and flexible distribution pathways.

  GlobeNewswire Inc.
• BioCryst Announces Sale of European ORLADEYO® (berotralstat) Business to Neopharmed Gentili for up to $264 Million

  BioCryst Pharmaceuticals has agreed to sell its European ORLADEYO business to Neopharmed Gentili for up to $264 million, with $250 million paid upfront. The company plans to use proceeds to retire term debt and expects to end 2027 with approximately $700 million in cash.

  Benzinga
• Why BioCryst Pharmaceuticals Stock Tumbled by 10% Today

  BioCryst Pharmaceuticals stock fell 10% after the company reported Q4 earnings that missed analyst estimates. However, the company raised guidance for 2025 Orladeyo sales and overall revenue, indicating potential for growth.

  The Motley Fool
• BioCryst Pharmaceuticals (BCRX) Reports Q1 Loss, Tops Revenue Estimates

  BioCryst (BCRX) delivered earnings and revenue surprises of 26.09% and 8.37%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

  Zacks Investment Research

  Featured Companies: ACRS